Ekso Bionics Stories Preliminary Fourth Quarter and Full Year 2020 Fiscal Final results

RICHMOND, Calif., Jan. 13, 2021 (Globe NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an business chief in exoskeleton technological innovation for professional medical and industrial use, nowadays introduced preliminary leading line monetary benefits for the fourth quarter and fiscal 12 months finished December 31, 2020.

Complete revenue for the fourth quarter of 2020 is an estimated $2.3 million, as opposed to whole profits of $3.7 million in the fourth quarter of 2019. Full earnings for fiscal 12 months 2020 is estimated to be somewhere around $8.9 million, when compared to $13.9 million in 2019.

Money at December 31, 2020 was $12.9 million, in comparison to $10.9 million at December 31, 2019.

“Our believed fourth quarter 2020 income mirrored stable functionality as we executed on vital initiatives although navigating by means of COVID-connected marketplace issues,” commented Jack Peurach, President and Main Government Officer of Ekso Bionics. “During the quarter, we continued to achieve traction with our community operator technique in the medical small business. We imagine that our new subscription design, which reduces capital constraints, will aid further strategic deals and further expand our set up base in 2021. We are also happy that our latest industrial innovation, EVO™, created sturdy consumer exhilaration and solid first adoption developments adhering to its August 2020 launch. Searching forward, we continue to be confident that as the COVID situation increases, our growing pipeline of opportunities will construct greater momentum supported by our compelling value propositions in equally the professional medical and industrial fronts.”

The predicted benefits talked about in this press release are primarily based on management’s preliminary, unaudited analysis of fiscal outcomes for the period of time and calendar year ended December 31, 2020. As of the date of this press launch, the Company has not accomplished its financial statement reporting process for the interval and 12 months finished December 31, 2020, and the Company’s unbiased registered accounting business has not audited the preliminary fiscal knowledge talked about in this press release. Throughout the study course of the Company’s quarter-end closing treatments and evaluate course of action, the Company may determine products that would require it to make adjustments, which might be materials to the information offered above. As a end result, the estimates earlier mentioned represent forward-looking details and are issue to pitfalls and uncertainties, together with probable changes to preliminary operating results. The Business expects to report finish fourth quarter and comprehensive year 2020 economical benefits in the course of the past week of February 2021.

About Ekso Bionics® 
Ekso Bionics® is a leading developer of exoskeleton options that amplify human likely by supporting or improving energy, endurance and mobility throughout clinical and industrial programs. Launched in 2005, the Business proceeds to make on its sector-major expertise to design some of the most chopping-edge, progressive wearable robots readily available on the marketplace. Ekso Bionics is the only exoskeleton firm to offer you systems that array from supporting all those with paralysis to stand up and wander, to enhancing human abilities on position internet sites across the world. The Corporation is headquartered in the San Francisco Bay Spot and is stated on the Nasdaq Cash Market beneath the symbol “EKSO.” For additional information, take a look at:  www.eksobionics.com  or follow @EksoBionics on Twitter.

Ahead-Searching Statements
Any statements contained in this push launch that do not describe historical points may perhaps constitute ahead-wanting statements. Ahead-wanting statements might involve, with out limitation, statements regarding (i) the options and goals of administration for long term operations, like programs or aims relating to the layout, enhancement and commercialization of human exoskeletons, strategies or approach relating to the promoting and adoption and acceptance of the Company’s solutions and possible for adoption of the Company’s products and solutions by the sector, (ii) estimates or projection of economical outcomes, money affliction, funds expenses, money composition or other financial things, (iii) the Company’s foreseeable future economic performance and (iv) the assumptions fundamental or relating to any statement described in factors (i), (ii) or (iii) over. These kinds of forward-looking statements are not meant to predict or ensure real benefits, general performance, gatherings or circumstances and may perhaps not be understood because they are centered upon the Company’s latest projections, strategies, goals, beliefs, anticipations, estimates and assumptions and are issue to a variety of risks and uncertainties and other influences, several of which the Firm has no management over. Real results and the timing of specific activities and circumstances may differ materially from these described by the ahead-looking statements as a result of these threats and uncertainties. Factors that may possibly influence or contribute to the inaccuracy of the ahead-searching statements or induce actual benefits to differ materially from anticipated or ideal outcomes may possibly contain, devoid of limitation, modifications ensuing from the Company’s finalization of its fiscal statements for and as of the interval and year finished December 31, 2020, info or new changes in information or instances that may well come about prior to the filing of the Company’s Once-a-year Report on Variety 10-K for the 12 months finished December 31, 2020 that are demanded to be bundled in this kind of once-a-year report, the Company’s incapability to get sufficient financing to fund the Company’s functions and needed to develop or increase our technology, the important length of time and sources connected with the growth of the Company’s solutions, the Company’s failure to achieve wide market acceptance of the Company’s solutions, the failure of our product sales and marketing corporation or associates to industry our merchandise effectively, adverse outcomes in future scientific scientific studies of the Company’s professional medical system products, the failure to obtain or manage patent safety for the Company’s technological know-how, failure to get or maintain regulatory acceptance to marketplace the Company’s professional medical devices, lack of products diversification, current or enhanced level of competition, the Company’s failure to put into practice the Company’s company plans or tactics and the impact of the COVID-19 pandemic. These and other aspects are recognized and explained in a lot more detail in the Company’s filings with the SEC. To discover additional about Ekso Bionics make sure you go to us at www.eksobionics.com or refer to our Twitter website page at @EksoBionics. The Enterprise does not undertake to update these ahead-looking statements.

Investor Contact:
David Carey
212-867-1768
[email protected]  

 

Della C. Mae

Next Post

Fundamental-earnings proposal by Suga adviser could be hard provide in Japan

Thu Jan 14 , 2021
© 共同通信社 The idea of Japan introducing a common standard earnings, a short while ago floated by one of Prime Minister Yoshihide Suga’s financial advisers, has caught the eye at a time when the coronavirus pandemic is stirring anxieties about career stability and social inequality. In the previous, some opposition […]